US FDA Approves Aston Sci.'s Phase 2 IND for Ovarian Cancer Vaccine, AST-201

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

US FDA Approves Aston Sci.'s Phase 2 IND for Ovarian Cancer Vaccine, AST-201

header-info

Sep, 12, 2023

This approval is based on results from a randomized, controlled trial where patients with newly diagnosed, stage 3 advanced ovarian cancer received the plasmid-based DNA vaccine alongside standard adjuvant chemotherapy following surgical intervention.

Access the full article to read more here.